REG - SkinBioTherapeutics - Conversion Notice and Total Voting Rights

SkinbiotherapeuticsAnnouncement

12/03/2024 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240312:nRSL4886Ga&default-theme=true

RNS Number : 4886G  SkinBioTherapeutics PLC  12 March 2024

 

SkinBioTherapeutics plc

("SkinBioTherapeutics" or "the Company")

 

Conversion Notice and Total Voting Rights

 

12 March 2024 - SkinBioTherapeutics plc, (AIM: SBTX, or the "Company"), the
life science business focused on skin health, announces that it received a
Conversion Notice on 4 March 2024 from Macquarie ("Macquarie") for £80,000 of
Convertible Bonds from the £5.0 million convertible bond facility announced
on 25 January 2024. The Company has drawn a total of £1,600,000 under the
Facility.

 

SkinBioTherapeutics will issue 1,108,524 ordinary shares of £0.01 per share
("Ordinary Shares") at a conversion price of 7.216800p per Ordinary Share.

 

Admission and Total Voting Rights

 

Application has been made for the 1,108,524 new ordinary shares, which will
rank pari passu in all respects with the existing ordinary shares of the
Company, to be admitted to AIM, which is expected to occur on or around 8.00
a.m. on 14 March 2024 ("Admission"). Upon Admission, the total number of
issued shares and the total number of voting rights in the Company will be
192,795,949.

 

The above figure of 192,795,949 should be used by shareholders in the Company
as the denominator for the calculations by which they will determine if they
are required to notify their interest in, or a change to their interest in,
the share capital of the Company under the Financial Conduct Authority's
Disclosure Guidance and Transparency Rules.

 

Conversion Update

 

Purusant to the two previous conversions announced on 9 February 2024 and 28
February 2024, a total of 1,324,484 Ordinary shares have been converted and
sold by Macquarie Bank/CLG which represents 13% of all trading volume in the
market during the month of February 2024.

 

Furthermore, Macquarie Bank/CLG have agreed to no further conversions for the
month of March unless price and volumes reach certain agreed higher
thresholds.

 

-Ends-

The information communicated in this announcement contains inside information
for the purposes of Article 7 of the Market Abuse Regulation (EU) No.
596/2014.

 

 

 For more information please contact:

 SkinBioTherapeutics plc                            Tel: +44 (0) 191 495 7325

 Stuart J. Ashman, CEO

 Manprit Randhawa, CFO

 Cavendish Capital Markets Limited                  Tel: +44 (0) 20 7220 0500

 (Nominated Adviser & Broker)

 Giles Balleny, Dan Hodkinson (Corporate Finance)

 Charlie Combe (Broking)

 Dale Bellis, Tamar Cranford-Smith (Sales)

 Instinctif Partners (financial press)              Tel: +44 (0) 20 7457 2020

 Melanie Toyne-Sewell / Jack Kincade                SkinBioTherapeutics@instinctif.com

 

 Notes to Editors

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The
Company's proprietary platform technology, SkinBiotix®, is based upon
discoveries made by Professor Catherine O'Neill and Professor Andrew McBain.

The Company is targeting a number of skin healthcare sectors, the most
advanced of which are cosmetic skincare and food supplements to modulate the
immune system by harnessing the gut-skin axis. In each area
SkinBioTherapeutics plans to exemplify its technology through human studies.
The Company's first product, AxisBiotix-Ps™, a food supplement to address
the symptoms of mild to moderate psoriasis.

The Company listed on AIM in April 2017 and is based in Newcastle, UK. For
more information, visit: www.skinbiotherapeutics.com and www.axisbiotix.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCJTMFTMTABMPI